Licensing Resources for Veterans
Office of Policy & Legislative Affairs
Construction Codes
Community and Health Systems
Corporations, Securities & Commercial Licensing Bureau.
Michigan Office of Administrative Hearings and Rules
Professional Licensing
Search is currently unavailable. Please try again later.
The web Browser you are currently using is unsupported, and some features of this site may not work as intended. Please update to a modern browser such as Chrome, Firefox or Edge to experience all features Michigan.gov has to offer.
Drug Utilization Reports offer data regarding dispensed controlled substance prescriptions reported to MAPS.
|
Total CS prescriptions dispensed |
% change from previous year |
|
|
2007 |
17,007,858 |
|
|
2008 |
17,400,640 |
2.31% |
|
2009 |
17,876,684 |
2.74% |
|
2010 |
18,954,172 |
6.03% |
|
2011 |
19,763,680 |
4.27% |
|
2012 |
20,991,020 |
6.21% |
|
2013 |
20,728,216 |
-1.25% |
|
2014 |
20,904,764 |
0.85% |
|
2015 |
21,472,326 |
2.71% |
|
2016 |
21,092,674 |
-1.77% |
| 2017 | 19,943,203 | -5.45% |
|
2018 (updated Nov 5, 2019) |
17,623,754 |
-11.63% |
| 2019 | 18,472,677 | 4.82% |
| 2020 | 17,785,603 | -3.72% |
| 2021 | 17,724,380 | -0.34% |
| 2022 | 17,538,316 | -1.05% |
A new statewide assessment has identified trends that will assist government agencies, lawmakers and local community leaders tailor laws, target resources, and design innovative programs to best address the opioid epidemic in Michigan.
The assessment overlays three years (2013-2015) of well-documented cases of unintentional overdose death with five years (2012-2017) of prescription records in the Michigan Automated Prescription System (MAPS). In total, more than 7.5 million patients receiving 103.2 million prescriptions over the last five years were linked to 5,261 overdose deaths.
The assessment provides valuable information about patterns of opioid usage in Michigan by detailing patient-level and aggregate trends of controlled-substance prescriptions and overdose deaths within the state.
A new study, the Michigan AWARxE/NarxCare Implementation Evaluation, is the nation’s first study evaluating the effectiveness of NarxCare. Appriss’s Michigan Implementation and Evaluation analyzes NarxCare risk scores and shows a decline in patients with a high potential to abuse prescription drugs.
The State of Michigan is covering the full cost of integration of MAPS into the clinical workflow of health systems, physician groups and pharmacies through at least September 30, 2025. Learn how to start the integration process.
